Sandostatin® LAR® (octreotide/IM injection)

• http://www.sandostatin.com
  (For Non U.S. Health Care Professionals Only)

SANDOSTATIN LAR CONTACT

Gloria Vanderham

Novartis Oncology Global Public Relations

office +1 862 778 4268

Gloria.Vanderham@novartis.com

Sandostatin® LAR® (octreotide/IM injection) is indicated for the treatment of:

Of patients with acromegaly:

• who are adequately controlled on s.c. treatment with Sandostatin
  
• in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective

Treatment of patients with symptoms associated with functional GEP NE tumors in whom symptoms are adequately controlled on s.c. treatment with Sandostatin:

Carcinoid tumours with features of the carcinoid syndrome.

• VIPomas
• Glucagonomas
• Gastrinomas (Zollinger-Ellison syndrome)
• Insulinomas-for pre-operative control of hypoglycemia as well as maintenance therapy
  
• GRFomas

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.